(Q36777803)

16 August 2017

1 reference

title

The economic implications of glaucoma: a literature review (English)

1 reference

16 August 2017

1 reference

Michael T Halpern

2

0 references

Jordana K. Schmier

object named as

Jordana K Schmier

series ordinal

1

0 references

author name string

Mechelle L Jones

series ordinal

3

1 reference

16 August 2017

1 January 2007

1 reference

16 August 2017

1 reference

16 August 2017

25

1 reference

16 August 2017

4

1 reference

16 August 2017

287-308

1 reference

https://scigraph.springernature.com/pub.10.2165/00019053-200725040-00003

16 August 2017

0 references

cites work

Cost analysis of early trabeculectomy versus conventional management in primary open angle glaucoma

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00019053-200725040-00003

Costing a community based screening programme for the detection of glaucoma

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00019053-200725040-00003

The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Collaborative Normal-Tension Glaucoma Study Group

21 January 2018

1 reference

12 December 2020

How much is the cost of visual impairment: caveat emptor

1 reference

12 December 2020

A multicenter, retrospective pilot study of resource use and costs associated with severity of disease in glaucoma.

1 reference

12 December 2020

A Markov modelled pharmacoeconomic analysis of bimatoprost 0.03% in the treatment of glaucoma as an alternative to filtration surgery in Italy

1 reference

12 December 2020

Evaluation of non-medical costs associated with visual impairment in four European countries: France, Italy, Germany and the UK.

1 reference

12 December 2020

Screening for primary open-angle glaucoma in the developed world: are we there yet?

1 reference

12 December 2020

Dosage cost analysis in glaucoma management.

1 reference

12 December 2020

Racial variations in the prevalence of primary open-angle glaucoma. The Baltimore Eye Survey

1 reference

12 December 2020

Resource use and costs of patients with glaucoma or ocular hypertension: a one-year study based on retrospective chart review in the Netherlands.

1 reference

12 December 2020

A cost analysis of the prostaglandin analogs.

1 reference

12 December 2020

Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report

1 reference

12 December 2020

Comparison of annual cost between brand and generic ocular beta-adrenergic blockers.

1 reference

12 December 2020

The treatment of newly diagnosed patients with glaucoma or with ocular hypertension in The Netherlands: an observational study of costs and initial treatment success based on retrospective chart review.

1 reference

12 December 2020

A persistency and economic analysis of latanoprost, bimatoprost, or beta-blockers in patients with open-angle glaucoma or ocular hypertension

1 reference

12 December 2020

Consumption of glaucoma medication

1 reference

12 December 2020

Direct costs of glaucoma management following initiation of medical therapy. A simulation model based on an observational study of glaucoma treatment in Germany.

1 reference

12 December 2020

Health economics, economic evaluation, and glaucoma

1 reference

12 December 2020

Costs of medical and surgical treatment of glaucoma

1 reference

12 December 2020

Cost of glaucoma in Canada: analyses based on visual field and physician's assessment

1 reference

12 December 2020

Switching patients with glaucoma or ocular hypertension from dual therapy to monotherapy: evaluation of brimonidine as a model

1 reference

12 December 2020

Clinical and economic impact of new trends in glaucoma treatment

1 reference

12 December 2020

Direct costs of glaucoma and severity of the disease: a multinational long term study of resource utilisation in Europe

1 reference

12 December 2020

Naturalistic, prospective study of glaucoma and ocular hypertension treatment in France: strategies, clinical outcomes, and costs at 1 year.

1 reference

12 December 2020

Cost effectiveness of screening for primary open angle glaucoma.

1 reference

12 December 2020

An economic analysis of switching to latanoprost from a beta-blocker or adding brimonidine or latanoprost to a beta-blocker in open-angle glaucoma or ocular hypertension.

1 reference

12 December 2020

The cost-effectiveness of early vitrectomy for the treatment of vitreous hemorrhage in diabetic retinopathy.

1 reference

12 December 2020

What is the direct cost of treatment of acute primary angle closure glaucoma? The Singapore model

1 reference

12 December 2020

Assessing the cost-effectiveness of switching from a β-blocker to latanoprost in the treatment of ocular hypertension

1 reference

12 December 2020

Glaucoma medical treatment--2002: does yearly cost now equal the year?

1 reference

12 December 2020

The economic burden of glaucoma and ocular hypertension: implications for patient management: a review

1 reference

12 December 2020

Cost considerations of medical therapy for glaucoma

1 reference

12 December 2020

Daily cost of beta-adrenergic blocker therapy

1 reference

12 December 2020

Costs of treating primary open-angle glaucoma and ocular hypertension: a retrospective, observational two-year chart review of newly diagnosed patients in Sweden and the United States

1 reference

12 December 2020

Cost analysis of glaucoma medications: a 3-year review

1 reference

12 December 2020

Medical predictive factors of glaucoma treatment costs

1 reference

12 December 2020

The prevalence of glaucoma in a population-based study of Hispanic subjects: Proyecto VER.

1 reference

12 December 2020

How prostaglandins have changed the medical approach to glaucoma and its costs: an observational study of 2228 patients treated with glaucoma medications

1 reference

12 December 2020

A cost-effectiveness comparison of bimatoprost versus latanoprost in patients with glaucoma or ocular hypertension

1 reference

12 December 2020

Naturalistic, prospective study of glaucoma and ocular hypertension treatment in France: Strategies, clinical outcomes, and costs at 2 years

1 reference

12 December 2020

Clinical and economic impacts of latanoprost 0.005% in first-line treatment of open-angle glaucoma and ocular hypertension in France

1 reference

12 December 2020

Patient preferences for eye drop characteristics: a willingness-to-pay analysis.

1 reference

12 December 2020

Glaucoma screening. A cost-effectiveness analysis

1 reference

12 December 2020

The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration.The AGIS Investigators

1 reference

12 December 2020

A Genetic Contribution to Intraocular Pressure: The Beaver Dam Eye Study

1 reference

12 December 2020

Economic evaluation of dorzolamide vs. pilocarpine for primary open-angle glaucoma.

1 reference

12 December 2020

Evaluation of quality of life for patients with glaucoma

1 reference

12 December 2020

Glaucoma screening clinic in general practice: prevalence of occult disease, and resource implications

1 reference

12 December 2020

Use of eye care and associated charges among the Medicare population: 1991-1998.

1 reference

12 December 2020

Preferences for eye drop characteristics among glaucoma specialists: a willingness-to-pay analysis

1 reference

12 December 2020

Medical therapy cost considerations for glaucoma

1 reference

12 December 2020

The value of screening for glaucoma with tonometry

1 reference

12 December 2020

Bias in published cost effectiveness studies: systematic review

1 reference

12 December 2020

A modeled economic analysis of a digital tele-ophthalmology system as used by three federal health care agencies for detecting proliferative diabetic retinopathy

1 reference

12 December 2020

The cost-effectiveness of bimatoprost 0.03% in the treatment of glaucoma in adult patients--a European perspective

1 reference

12 December 2020

A multicentre, retrospective study of resource utilization and costs associated with glaucoma management in France and Sweden

1 reference

12 December 2020

Impact of visual impairment on use of caregiving by individuals with age-related macular degeneration

1 reference

12 December 2020

Health and economic outcomes modeling practices: a suggested framework

1 reference

12 December 2020

Comparing costs of monitoring glaucoma patients: hospital ophthalmologists versus community optometrists.

1 reference

12 December 2020

Projected impact of travoprost versus both timolol and latanoprost on visual field deficit progression and costs among black glaucoma subjects

1 reference

12 December 2020

Prevalence of open-angle glaucoma among adults in the United States

1 reference

12 December 2020

Cost-effectiveness of trachoma control in seven world regions

1 reference

12 December 2020

Cost-utility analysis of screening intervals for diabetic retinopathy in patients with type 2 diabetes mellitus.

1 reference

12 December 2020

Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices--Modeling Studies.

1 reference

12 December 2020

The cost of antiglaucoma medications

1 reference

12 December 2020

Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery

1 reference

12 December 2020

The burden of age-related macular degeneration

1 reference

12 December 2020

Prevalence of glaucoma. The Beaver Dam Eye Study.

1 reference

12 December 2020

Modeling cost of treatment with new topical treatments for glaucoma. Results from France and the United Kingdom.

1 reference

12 December 2020

Cost-effectiveness of monotherapy treatment of glaucoma and ocular hypertension with the lipid class of medications

1 reference

12 December 2020

Prevalence of open-angle glaucoma and ocular hypertension in Latinos: the Los Angeles Latino Eye Study

1 reference

12 December 2020

Association between mean intraocular pressure, disease stability and cost of treating glaucoma in Canada

1 reference

12 December 2020

Cost analysis of glaucoma medications

1 reference

12 December 2020

10.2165/00019053-200725040-00003

Identifiers

DOI

1 reference

PubMed ID

17402803

Dimensions Publication ID

16 August 2017

0 references

1 reference

PubMed ID

17402803